Skip to main content

Table 6 Baseline characteristics of 120 PMN patients for detecting circulating anti-PLA2R antibody

From: The association between variants in PLA2R and HLA-DQA1 and renal outcomes in patients with primary membranous nephropathy in Western China

  PLA2R low risk + HLA low risk PLA2R low risk + HLA high risk PLA2R high risk + HLA low risk PLA2R high risk + HLA high risk P
n = 12 n = 7 n = 60 n = 41
Male/female 8/4 4/3 36/24 24/17 0.963
Age (year) 48.33 ± 15.47 54.86 ± 15.08 49.95 ± 15.28 52.71 ± 9.30 0.564
Scr (μmol/L) 79.75 ± 28.70 73.78 ± 22.95 72.87 ± 39.41 73.30 ± 27.08 0.935
Urea (mmol/L) 5.78 ± 1.90 6.08 ± 2.74 6.43 ± 5.19 5.48 ± 2.21 0.707
eGFR (ml/ (min·1.73m2)) 94.49 ± 27.64 91.90 ± 27.57 99.98 ± 23.42 94.26 ± 21.48 0.577
Urine protein (g/24 h) 8.30 ± 7.67 3.30 ± 2.07 4.73 ± 3.68 4.38 ± 3.09 0.010
HGB (g/L) 132.25 ± 17.11 132.14 ± 15.66 132.08 ± 15.72 133.07 ± 17.52 0.993
Alb (g/L) 23.11 ± 5.67 28.44 ± 7.23 25.74 ± 5.89 32.40 ± 38.65 0.465
anti-PLA2R ( +)/ ( −) 5/7 5/2 45/15 36/5 0.012
anti-PLA2R ( +) (%) 41.6 71.4 75.0 87.8